Print

Cell>Point Completes Phase 2 of Cancer Diagnostic Phase 2/3 Trial  
6/29/2010 8:17:08 AM

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer (NSCLC).
//-->